{"slug":"ss-31-gut","verification":{"valid":true,"entries":2,"head":"95964720ddc6a7bcf6cc236e2280ce22121375af87b3c89b96887feb44d986fb"},"energy":{"passes":2,"tokens_in":36102,"tokens_out":2788,"tokens_total":38890,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"95964720ddc6a7bcf6cc236e2280ce22121375af87b3c89b96887feb44d986fb"},"provenance":[{"ts":"2026-06-29T23:54:01.705Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Ss 31 for Gut\nSlug: ss-31-gut\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"ss-31\",\"name\":\"SS-31 (Elamipretide)\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"ss-31\",\"name\":\"SS-31 (Elamipretide)\",\"section_title\":\"Why SS-31 (Elamipretide) might help you\",\"layer\":\"mitochondrial\",\"steps\":[\"**Therefore for you:** If that layer is part of your problem, SS-31 (Elamipretide) is discussed because it targets repair (tissue) — not because it masks pain.\"],\"prose\":\"1. **Therefore for you:** If that layer is part of your problem, SS-31 (Elamipretide) is discussed because it targets repair (tissue) — not because it masks pain.\"}],\"drug_chains\":[],\"stimulant_chains\":[],\"stack_together\":\"Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\\n- **SS-31 (Elamipretide)** → mitochondrial\",\"section_headings\":[\"What's breaking down\",\"Why SS-31 (Elamipretide) might help you\",\"How these fit together\",\"What the evidence actually shows\",\"What scientists say\",\"What people say on Reddit\",\"What people say on X\",\"What we do not know\",\"Safety and limits\"],\"writer_rules\":[\"One ## section per compound in peptide_chains — do not merge into one","response":"{\n  \"slug\": \"ss-31-gut\",\n  \"title\": \"SS-31 (Elamipretide) Mitochondrial Support for Gut: Evidence Review\",\n  \"body\": \"## What's breaking down\\n\\nGut barrier integrity depends on intestinal epithelial cells maintaining tight junctions and low oxidative stress. Mitochondrial dysfunction in these cells can increase reactive oxygen species, disrupt cardiolipin in the inner membrane, impair ATP production, and trigger apoptosis. This process weakens tight junction proteins such as ZO-1 and occludin. The result is higher paracellular permeability. Repair pathways that stabilize mitochondria can address the root layer rather than only downstream inflammation or symptoms.\\n\\n## Why SS-31 (Elamipretide) might help you\\n\\nIf mitochondrial oxidative stress and cardiolipin instability form part of your gut barrier challenge, SS-31 (Elamipretide) is discussed because it binds cardiolipin directly. Step one: the peptide accumulates in the inner mitochondrial membrane. Step two: it stabilizes cristae structure and supports electron transport chain efficiency. Step three: this reduces electron leak and ROS production while preserving ATP output. Step four: lower ROS can limit apoptosis and support maintenance of tight junction proteins. Therefore for you: If that layer is part of your problem, SS-31 (Elamipretide) is discussed because it targets repair (tissue) — not because it masks pain.\\n\\n## How these fit together\\n\\nSingle-compound focus. SS-31 (Elamipretide) maps to the mitochondrial layer of intestinal epithelial cell health. No sibling peptides are in scope for this review.\\n\\n## What the evidence actually shows\\n\\nHuman data specific to gut: none identified. Preclinical data: one in-vitro study examined mycophenolic acid (MPA)-induced damage in intestinal epithelial cells. MPA increased ROS, reduced tight junction expression, and raised apoptosis. SS-31 treatment lowered intracellular and intramitochondrial ROS, upregulated tight junction proteins, and reduced apoptosis ra","tokens_in":36102,"tokens_out":2788,"cost":0,"prev":"genesis","hash":"9ef6e05d33e4b0035faecc25cfe34a78a14f1fbd6440ea0bc01c0cf919820f42"},{"ts":"2026-07-17T02:42:04.241Z","model":"owner","action":"voxel_divide","prompt":"","input":"ss-31-gut","response":"18 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"9ef6e05d33e4b0035faecc25cfe34a78a14f1fbd6440ea0bc01c0cf919820f42","hash":"95964720ddc6a7bcf6cc236e2280ce22121375af87b3c89b96887feb44d986fb"}]}